3/24/2020 7:52:23 AM
TherapeuticsMD Appoints Paul Bisaro And Gail Naughton To Board
3/16/2020 6:09:00 AM
TherapeuticsMD Says Takes Steps To Ensure Safety Of Employees In View Of COVID-19
2/20/2020 7:28:02 AM
TherapeuticsMD Q4 Loss Per Share $0.19 Vs Loss $0.72 Last Year
2/13/2020 6:34:39 AM
TherapeuticsMD And Afaxys Pharma, LLC Enter Agreement To Expand Access To ANNOVERA In US
2/3/2020 6:32:00 AM
TherapeuticsMD Announces Submission Of NDA Prior Approval Efficacy Supplement To FDA For Lower Dose Of BIJUVA
12/30/2019 7:00:12 AM
TherapeuticsMD Announces Amendment To Term Loan Financing Facility With TPG Sixth Street Partners
10/11/2019 7:09:00 AM
TherapeuticsMD Announces Presentations On ANNOVERA At 2019 Annual Meeting Of ASRM
10/29/2018 6:02:51 AM
TherapeuticsMD Announces FDA Approval Of TX-001HR: BIJUVA Capsules
9/20/2018 7:05:09 AM
TherapeuticsMD Announces FDA Grants Annovera Marketing Exclusivity As A New Chemical Entity
9/13/2018 7:04:42 AM
TherapeuticsMD Reports Commercial Availability Of Imvexxy 4 Mcg
8/1/2018 9:39:16 PM
TherapeuticsMD Announces Pricing Of Public Offering And Registered Direct Offering For Aggregate Proceeds Of $85 Mln
7/31/2018 4:14:33 PM
Knight Therapeutics Receives License To TX-004HR And TX-001HR In Canada And Israel From TherapeuticsMD
7/30/2018 6:18:07 AM
TherapeuticsMD Q2 Net Loss $33.2 Mln Or $0.15/Shr Vs Loss $19.7 Mln Or $0.10/Shr Last Year
6/6/2018 7:04:15 AM
TherapeuticsMD Announces Multiple Presentations At International Menopause Society’s 16th World Congress